⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HALO News
Halozyme Therapeutics, Inc.
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
prnewswire.com
HALO
Crayola Announces First Class of Global Ambassadors Ahead of Annual Celebration of Creativity in Schools
prnewswire.com
HALO
DeGirum Announces Workspaces in AI Hub for Edge AI Developers
prnewswire.com
HALO
INTC
RRC
MEMX
BCH
Crayola Launches Groundbreaking Tool to Help Adults Discover Their Creative Styles
prnewswire.com
HALO
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
businesswire.com
VZ
FI
HALO
SMCI
INVX
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
prnewswire.com
HALO
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity USA - English APAC - English APAC - Traditional Chinese
prnewswire.com
HALO
SKYE
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
globenewswire.com
HALO
SKYE
Haloid Solutions Disrupts LMR Radio Repairs with No-Cost Repair Promotion for Mission-Critical Communications Equipment
prnewswire.com
HALO
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
prnewswire.com
HALO